Saturday, March 28th17.4°C
25657

Drugmaker Merck's Q4 profit, sales fall due to generic competition, unfavourable exchange rates

Merck & Co.'s fourth-quarter profit dropped 14 per cent, with its aggressive cost cutting not enough to offset restructuring charges, generic competition to former blockbuster medicines and unfavourable currency exchange rates.

Results just missed Wall Street expectations, and even though Merck said 2014 will be a "trough year" for revenue, shares briefly hit a six-year high of $55.20. That's because the world's third-biggest drugmaker separately announced new, potentially lucrative alliances.

Merck will collaborate with three other drugmakers to test its hot experimental cancer drug, called MK-3475, in combination with theirs. It's in a new class of cancer medicines meant to restore the immune system's natural ability to spot and target cancer cells.

In morning trading, Merck shares rose $1.05, or 2 per cent, to $54.56.

Merck reported net income of $781 million, or 26 cents per share, down from $908 million, or 30 cents per share, a year earlier.

The maker of the Type 2 diabetes pill Januvia said that excluding one-time items, net income was $2.6 billion, or 88 cents per share — a penny shy of analysts' expectations.

Revenue totalled $11.32 billion, down 4 per cent. Analysts expected $11.36 billion.

Sales were lower than expected for Januvia, HPV vaccine Gardasil and a few other products, but higher than expected for immune disorder drug Remicade, HIV drug Isentress and cholesterol pills Zetia and Vytorin.

Two issues dominated Merck's conference call with analysts. Asked about MK-3475's potential, as a solo treatment and combined with drugs from new partners Pfizer Inc., Amgen Inc. and Incyte Corp., Merck said it's too soon to tell.

Analysts also asked about Merck's strategic review of its animal health business, the world's second largest, and its consumer health business, which sells Coppertone sun care items and nonprescription Claritin allergy pills. CEO Kenneth Frazier said he's determining whether they'd be more valuable inside or outside of Merck and will decide by year's end.

Bernstein Research analyst Dr. Timothy Anderson wrote that he thinks Merck might keep animal health, which Frazier said he likes for a number of reasons, rather than consumer health, which is limited by small size. Swiss drugmaker Novartis AG reportedly is weighing deals including swapping its animal health business for Merck's consumer segment.

Merck, based in Whitehouse Station, N.J., forecast 2014 profit of $3.35 to $3.53 per share, excluding one-time items. Analysts are projecting $3.46 per share.

For all of 2013, Merck reported net income of $4.04 billion, or $1.47 per share, on revenue of $44.03 billion.

___

Follow Linda A. Johnson at http://twitter.com/LindaJ_onPharma

The Canadian Press


Read more Business News

25185


Recent Trending




Today's Market
S&P TSX14812.42-57.38
S&P CDNX681.43+1.87
DJIA17712.66+34.43
Nasdaq4891.22+27.86
S&P 5002061.02+4.87
CDN Dollar0.7928-0.0082
Gold1196.30-8.80
Oil48.43-3.00
Lumber282.40-3.60
Natural Gas2.62-0.05

 
Okanagan Companies
Pacific Safety0.125-0.005
Knighthawk0.010.00
QHR Technologies Inc1.50+0.00
Cantex0.03-0.01
Anavex Life Sciences0.219+0.009
Metalex Ventures0.04-0.01
Russel Metals24.50-0.18
Copper Mountain Mining1.13+0.00
Colorado Resources0.125+0.010
ReliaBrand Inc0.006-0.001
Sunrise Resources Ltd0.045+0.000
Mission Ready Services0.255+0.020
Decisive Dividend Corporation1.80+0.02

 



25718

FEATURED Property
2228768106-2350 Stillingfleet Road
1 bedrooms 1 baths
$159,000
more details
image2image2image2
Click here to feature your property
Please wait... loading


CRA Notice of Assessment

Many Canadians rush to file their taxes on time each year and don’t think about it until the next year. One of the most overlooked notices received from the CRA annually is the annual Notice of ...


Medical confidential?

If ICBC asks your doctor for your information you may wonder: Can ICBC ask my doctor for my medical information? Can ICBC request a medical report from my doctor without my consent? What is ICBC entit...


Stay out of sales limbo!

Have you ever had a series of good meetings with a prospect … gathered all kinds of information … and given what you thought was a great presentation … only to receive a response ...

_








Member of BC Press Council


25577